The April 2024 landmark paper proposing BPC-157 as a cytoprotection mediator with neurotransmitter-like activity represents a conceptual breakthrough in understanding how this gastric pentadecapeptide might treat mental health conditions
[DOI] [PMC free article] [PubMed] [Google Scholar] 147.Banach M., Serban C., Sahebkar A., Ursoniu S., Rysz J., Muntner P., Toth P.P., Jones S.R., Rizzo M., Glasser S.P., et al
Percent Daily Values are based on a 2,000 calorie diet
JAMA 311 , 12091217 (2014)
Decreased appetite: Some users have reported a decrease in appetite with L-carnitine supplementation
Based on announcements in early 2026, the FDA and HHS signaled reclassifying a group of peptides, including BPC-157, TB-500, and injectable GHK-Cu, toward Category 1, which makes them eligible for use by licensed compounding pharmacies preparing individualized medications under a prescription